BTIG analyst Sung Ji Nam maintained a Buy rating on Quotient (QTNT) on June 2 and set a price target of $13.00. The company’s shares closed last Tuesday at $4.35.
According to TipRanks.com, Nam is a 5-star analyst with an average return of 20.6% and a 69.5% success rate. Nam covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Genetron Holdings, and Fulgent Genetics.
Currently, the analyst consensus on Quotient is a Moderate Buy with an average price target of $9.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.77 and a one-year low of $3.41. Currently, Quotient has an average volume of 623.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quotient Ltd. is a commercial-stage diagnostics company. It provides immunohematology products to hospitals and blood banks. The company develops, manufactures and sells conventional reagent products to equipment manufacturers. It engages in transfusion diagnostics, which focuses on blood grouping and serological disease screening. Quotient was founded on January 28, 2012 and is headquartered in Eysins, Switzerland.
